Dr. Andrew M. Evens is a physician-scientist at the Rutgers Cancer Institute of New Jersey, where he is Associate Director for Clinical Services and Director of the Lymphoma Program. In addition, he is the Medical Director of the Oncology Service Line for the RWJBarnabas Health system. Dr. Evens completed a Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, where he was also Director of Translational Therapeutics. Prior to his Rutgers Cancer Institute appointment, Dr. Evens served as Chief of the Division of Hematology/Oncology at Tufts Medical Center and as Director of the Tufts Cancer Center in Boston, MA.

Dr. Evens is an associate editor for the British Journal of Haematology and serves on the editorial board for the Journal of Clinical Oncology. He is a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and has been a member of several clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group.  Dr. Evens is also an elected member of the Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and he is involved in multiple national and international educational forums and events.

I completed a prior fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 10 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.

My clinical expertise and research interests are fully dedicated to the field of lymphoma (i.e., Hodgkin lymphoma and non-Hodgkin lymphoma). Over the past 15+ years, I have been the principal investigator of more than 80 national and international cancer clinical trials that have included phase I, II, and III studies, many which have been “investigator-initiated” trials studying new and novel targeted agents for the treatment of lymphoid malignancies. In addition to my clinical research, I also manage a translational laboratory studying the biology of lymphoma and to discover new and novel treatments for patients. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) and the NCI since 2005. This has resulted in 200+ research abstracts at national and international cancer research symposiums, 150+ manuscripts in peer-reviewed publications, and 20+ book chapters all with an emphasis on the biology, prognosis, and treatment of lymphoma.

My involvement in the advancement of cancer research has also included leadership roles in academic journals, symposiums, cancer advocacy groups, and international committees. I was an associate editor for the British Journal of Haematology and on the editorial board for the Journal of Clinical Oncology and am the inaugural editor in chief for the open access journal, eJHaem. I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and I have been a member of several additional clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. Furthermore, I am Co-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group and am honored to be an elected member of the North American Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and a member of the Board of Trustees for the Leukemia & Lymphoma Society (LLS) New Jersey Chapter. Finally, I am involved and help lead a multitude of regional, national, and international educational forums and events.

Positions:
Associate Director for Clinical Services at Rutgers Cancer Institute of New Jersey
Medical Director of the Oncology Service Line, RWJBarnabas Health
Director, Lymphoma Program, Division of Blood Disorders

Clinical Expertise:
Hodgkin lymphoma, non-Hodgkin lymphoma (all types), chronic lymphocytic leukemia, and autologous hematopoietic stem cell (or bone marrow) transplantation.

Research Interests:
Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)
Chronic lymphocytic leukemia and other lymphoid malignancies
Clinical trials
Translational studies, including lymphoma biology and drug discovery
Systems biology and biomarker analyses
Lymphoma epidemiology
Health Outcomes, including Pharmacovigilance and Decision Making

I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey (CINJ) as the Associate Director for Clinical Services, Medical Director of the Oncology Service Line for RWJBarnabas Health, and Director of the Lymphoma Program. Rutgers Cancer Institute is unique in that it is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center. Our mission is to deliver integrated cancer care across the health system with access to academic expertise and innovative cancer therapies not available elsewhere in the state.


Title

Cited By

Year

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

907

2009

Pure red-cell aplasia and epoetin therapy

495

2004

The genetic landscape of mutations in Burkitt lymphoma

491

2012

Genetic heterogeneity of diffuse large B-cell lymphoma

479

2013

Genetic and functional drivers of diffuse large B cell lymphoma

397

2017

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

349

2014

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

318

2011

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

277

2013

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era

270

2010

Oxidative stress and apoptosis: a new treatment paradigm in cancer

239

2006

T-cell non-Hodgkin lymphoma

228

2006

The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future

224

2004

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

223

2007

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

222

2007

US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest …

218

2016

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

212

2007

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs

210

2010

Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the …

181

2007

Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer

171

2006

Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations

166

2012

Your Cancer Care is too Important to Wait

Minimizing your exposure to COVID-19 doesn’t require sacrificing cancer care or preventive services. Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are taking extra precautions to ensure that patients can continue to receive exceptional care close to home.
01-Jun-2020 08:00:26 AM EDT

Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma

Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.
29-May-2020 04:05:28 PM EDT

"In early-stage Hodgkin lymphoma, the continuing discussion still today revolves around the decision-making process of whether the recommendation is for combined modality therapy—in other words, chemotherapy, followed by consolidative radiotherapy—or chemotherapy alone".

- Treating Newly-Diagnosed Hodgkin Lymphoma

"We saw that, versus giving concurrent therapy, giving sequential, we saw much less neurotoxicity. At the end of the day, we were quite pleased to see a progression‑free survival rate in older patients almost comparable to younger patients, with progression‑free survival rate in the 80% range".

- Treating Newly-Diagnosed Hodgkin Lymphoma

Available for logged-in users onlyLogin HereorRegister
close
0.16611